ACT NOW —
Add VETMEDIN to your standard treatment protocol for CHF
Standard CHF treatment
There is no cure for canine congestive heart failure (CHF), and surgery to prevent further cardiac deterioration is rarely practical in canine patients. As a result, CHF treatment focuses on reducing clinical signs to help improve and extend life.1
As appropriate based on individual patient needs, current cardiac treatment protocols for dogs exhibiting clinical signs of CHF include:2-4
- VETMEDIN to reduce preload and afterload, increase cardiac output, and dilate veins and arteries.1,5,6
- Diuretics, such as furosemide, to help reduce fluid accumulation in the lungs, chest cavity, and/or abdomen.
- Angiotensin-converting enzyme (ACE) inhibitors to help reduce vascular resistance.
Studies show benefits of early VETMEDIN use in dogs exhibiting clinical signs
of CHF.1-4
Important safety information
VETMEDIN should not be given in case of hypertrophic cardiomyopathy, aortic stenosis, or any other clinical condition where an augmentation of cardiac output is inappropriate for functional or anatomical reasons.
The safety of VETMEDIN has not been established in dogs with:
- Asymptomatic heart disease
- Heart failure caused by etiologies other than atrioventricular valvular insufficiency or dilated cardiomyopathy
- Dogs younger than 6 months of age
- Dogs with congenital heart defects
- Dogs with diabetes mellitus or other serious metabolic diseases
- Dogs used for breeding or pregnant or lactating bitches
References:
1. Gordon SG, Miller MW, Saunders AB. Pimobendan in heart failure—a silver bullet? J Am Anim Hosp Assoc. 2006;42(2):90–93. 2. Lombard CW, Jöns O, Bussadori CM; for the VetSCOPE Study. Clinical efficacy of pimobendan versus benazepril for the treatment of acquired atrioventricular valvular disease in dogs. J Am Anim Hosp Assoc. 2006;42(4):249–261. 3. Häggström J, Boswood A, O’Grady M, et al. Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study. J Vet Intern Med. 2008;22(5):1124–1135. 4. Atkins C, Bonagura J, Ettinger S, et al. Guidelines for the diagnosis and treatment of canine chronic valvular heart disease. J Vet Intern Med. 2009;23(6):1142–1150. 5. Pagel PS, Hettrick DA, Warltier DC. Influence of levosimendan, pimobendan, and milrinone on the regional distribution of cardiac output in anaesthestized dogs. Br J Pharmacol. 1996;119(3):609–615. 6. Van Meel JCA, Diederen W. Hemodynamic profile of the cardiotonic agent pimobendan. J Cardiovasc Pharmacol. 1989;14(Suppl 29):S1–S6.
VETMEDIN is a registered trademark of Boehringer Ingelheim Vetmedica GmbH,
licensed to Boehringer Ingelheim Vetmedica, Inc.